Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the rectum
Stage/Subtype:  adenocarcinoma of the rectum
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 37 for your search:
Start Over
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
Quinacrine Hydrochloride and Capecitabine in Treating Patients with Metastatic or Recurrent Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: GI-078, NCI-2016-00139, NCT01844076
Guadecitabine and Irinotecan Hydrochloride or Regorafenib or TAS-102 Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, CIR00004735, CIR00013885, CIR0002117, j1369, NA_00085870, NCT01896856
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204 / ECHO-204, NCI-2015-00040, NCT02327078
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
Irinotecan Hydrochloride and Cetuximab with or without Ramucirumab in Treating Patients with Advanced Colorectal Cancer with Progressive Disease after Treatment with Bevacizumab-Containing Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7208, NCI-2011-02018, CDR0000666736, ECOG-E7208, NCT01079780
Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2011-00375, NCT01312857
Combination Chemotherapy, Bevacizumab, and Cholecalciferol in Treating Patients with Previously Untreated Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-436, NCI-2012-00662, NCT01516216
Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Relapsed or Refractory Colorectal Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1214, NCI-2012-01337, CIR00009096, NA_00069666, NCI-2013-01567, NCT01639131
Panitumumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Combination Chemotherapy and Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OSU-11131, NCI-2013-00432, 2012C0033, NCT01814501
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin before Surgery in Treating Patients with Stage II-III Rectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3R-12-2, NCI-2013-01069, 3C-12-2, HS-12-00726, ML28263, NCT01871571
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NCT01876511
Chemoradiation or Brachytherapy before Surgery in Treating Patients with Rectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1360, NCI-2014-00731, NA_00082167, NCI-2014-00125, NCT02017704
Regorafenib in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-211, NCI-2014-00002, NCT02023333
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-21-02, NCI-2014-00908, NCT02096354
Genetic Testing in Determining Irinotecan Hydrochloride Dose in Patients with Metastatic Colorectal Cancer Receiving FOLFIRI and Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1317, NCI-2014-01408, 13-3413, NCT02138617
Low Dose Whole Pelvic Radiation Therapy and Fluorouracil, Leucovorin Calcium, and Oxaliplatin in Treating Patients with Newly Diagnosed Stage IIIA-IIIB Rectal Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GCC 1314, NCI-2015-02142, 1314GCC, 15654748, HP-00060641, NCT02319304
Lower or Standard Dose Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU021407I, NCI-2015-00011, NCT02368886
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13050, NCI-2015-01790, NCT02425683
Regorafenib in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 70 and over
Trial IDs: 55555, NCI-2016-00641, NCT02466009
Ceritinib in Treating Patients with Activated Gastrointestinal Malignancies That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-0802, NCI-2016-00335, NCT02638909
Veliparib and Combination Chemotherapy in Treating Patient with Locally Advanced Rectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GI002, NCI-2016-00222, NCT02921256
Biweekly Intraperitoneal Oxaliplatin with Systemic Capecitabine and Bevacizumab for Patients with Peritoneal Carcinomatosis from Appendiceal or Colorectal Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-0136 / 201107017, NCI-2011-01043, 10-0136, NCT01061515
Chemotherapy, Radiation Therapy, and Midostaurin in Treating Patients with Locally Advanced Rectal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-457, NCI-2011-03089, CPKC412AUS09T, NCT01282502
Start Over